Logo undefined
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. inflammation chronic
Show results for
Products
Services
Applications

Companies

News
Articles
Books
Downloads
Videos

Refine by
Date

  • Older

Inflammation Chronic Articles & Analysis

26 news found

Amerigo Scientific Releases Optimal ZediXclusive TG6-ab ELISA (IgA) Kits to Detect TG6-Autoantibodies in Human Sera

Amerigo Scientific Releases Optimal ZediXclusive TG6-ab ELISA (IgA) Kits to Detect TG6-Autoantibodies in Human Sera

Celiac disease is the most common chronic inflammation of the small intestine triggered by cereal gluten/gliadin uptake in genetically susceptible individuals. ...

ByAmerigo Scientific


Alfa Chemistry Newly Releases Phospholipids, Modified Lipids, and Functionalized Lipids

Alfa Chemistry Newly Releases Phospholipids, Modified Lipids, and Functionalized Lipids

Bioactive lipids are consistently involved in chronic inflammation for pathological characterization, such as cancer, diabetes, atherosclerosis, asthma, inflammatory bowel disease, as well as autoimmune and neurodegenerative disorders. ...

ByAlfa Chemistry


Oxford Brain Diagnostics’ grey matter quality measure selected as secondary outcome for Alzheimer’s Phase 2 clinical trial

Oxford Brain Diagnostics’ grey matter quality measure selected as secondary outcome for Alzheimer’s Phase 2 clinical trial

Oxford Brain Diagnostics, a software company focused on developing diagnostics that identify changes in the brain at a cellular level, today announced that their Cortical Disarray Measurement (CDM®) has been appointed as a secondary outcome measure for a Randomized, PlaceboControlled, Double-Blind Study of XPro™ in Patients with Mild Alzheimer’s Disease with Biomarkers of ...

ByOxford Brain Diagnostics Ltd.


ÂŁ1.1 million project to develop new biodegradable stents

ÂŁ1.1 million project to develop new biodegradable stents

However, these metal stents are associated with early blood clots and long-term chronic inflammation at the stented site. This triggers recurrence of blockages within one to two years (also known as in-stent restenosis) leading to readmissions, repeated revascularisation and huge hospital costs. ...

ByArterius Limited


ANGANY Gaining Momentum for Plant-Based Immunotherapy Platform

ANGANY Gaining Momentum for Plant-Based Immunotherapy Platform

” About ANGANY ANGANY is a Franco-Canadian biopharmaceutical company that has developed a novel immunotherapy platform with broad applications in allergy, autoimmune diseases, chronic inflammation and cancer. ANGANY’s immunotherapy platform is based on a family of proprietary synthetic enveloped bioparticles that show a strong immunomodulatory ...

ByAngany Inc.


TikoMed and IQVIA announce a strategic collaboration for the development of TIKOMED’s lead drug platform candidate ILB®

TikoMed and IQVIA announce a strategic collaboration for the development of TIKOMED’s lead drug platform candidate ILB®

Today, Swedish biopharmaceutical company TikoMed AB and IQVIA announce a key strategic collaboration with the aim to accelerate the development of TikoMed’s lead drug platform candidate ILB®, a broad-spectrum small molecule drug candidate with curative potential in a wide range of diseases driven by acute and chronic inflammation. The collaboration ...

ByTIKOMED AB


The Lancet Publishes Positive Results from Capricor Therapeutics` Phase 2 Study Evaluating CAP-1002 in Late-Stage Duchenne Muscular Dystrophy

The Lancet Publishes Positive Results from Capricor Therapeutics` Phase 2 Study Evaluating CAP-1002 in Late-Stage Duchenne Muscular Dystrophy

About Duchenne Muscular Dystrophy Duchenne muscular dystrophy is a devastating genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart and respiratory muscles. Patients suffering from DMD typically lose their ability to walk in their teenage years and generally die of cardiac or respiratory complications by age 30. ...

ByCapricor Therapeutics, Inc.


LISCure Biosciences announces research collaboration with Mayo Clinic for rare liver diseases

LISCure Biosciences announces research collaboration with Mayo Clinic for rare liver diseases

Under the terms of the agreement, Mayo Clinic and LISCure metabolic disease R&D teams will collaborate on preclinical and clinical studies for rare liver diseases including primary sclerosing cholangitis (PSC), a cholestatic liver disease characterized by chronic liver inflammation and the progressive destruction of bile ducts. ...

ByLISCure Biosciences Inc.


Sight Sciences Receives FDA 510(k) Clearance of the TearCare System for Treatment of Meibomian Gland Dysfunction (MGD), the Leading Cause of Dry Eye Disease

Sight Sciences Receives FDA 510(k) Clearance of the TearCare System for Treatment of Meibomian Gland Dysfunction (MGD), the Leading Cause of Dry Eye Disease

If left untreated, MGD can present serious consequences, including ocular surface damage, changes in tear film stability, inflammation, pain, chronic dry eye, and other symptoms that can greatly impair a person’s daily life and vision. ...

BySight Sciences, Inc.


Winner announcement of EACR & Novosanis Research Grant: Cancer Biomarker Detection in Urine

Winner announcement of EACR & Novosanis Research Grant: Cancer Biomarker Detection in Urine

We are pleased to announce that Dr Barbara Guinn from University of Hull UK is the winner of the EACR & Novosanis Grant for Cancer Biomarker Detection in Urine. The grant awards the most impactful proposal in cancer related research using urine as a sample type, which has shown to be an emerging non-invasive liquid biopsy. For urine sample collection, the Colli-Pee device will be provided by ...

ByNovosanis NV


Hydrogen Water Maker and Its Benefits

Hydrogen Water Maker and Its Benefits

If you don't do anything about this oxidative stress, you may suffer from chronic inflammation with the passage of time. In a research study, researchers found that 20 patients experienced a reduction in their total cholesterol and LDL levels after the consumption of hydrogen-rich water for up to 10 weeks. ...

ByHuizhou Unionwell Technology Co., Ltd


Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC)

Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC)

About Inflammatory Bowel Disease Inflammatory bowel disease (IBD) is a debilitating, life-long condition that results from chronic inflammation of the intestinal tract. The most common forms of IBD are ulcerative colitis and Crohn's disease, which are both characterized by diarrhea, rectal bleeding, abdominal pain, fatigue and weight loss that can lead to ...

ByVedanta Biosciences, Inc


SFA Therapeutics, Inc. announces start of phase 1B clinical trial in the treatment of mild-to-moderate plaque psoriasis

SFA Therapeutics, Inc. announces start of phase 1B clinical trial in the treatment of mild-to-moderate plaque psoriasis

SFA is focused on proprietary drugs to treat chronic inflammation, which been implicated in a wide range of diseases, including Hepatocellular Carcinoma (liver cancer), Psoriatic Arthritis, Rheumatoid Arthritis, Lupus (SLE), Inflammatory Bowel Disease (IBD), Crohn’s Disease, and Chronic Liver Disease. ...

BySFA Therapeutics, Inc.


Hydrogen Peroxide provides Clues to Immunity, Wound Healing, Tumor Biology - Puroxi

Hydrogen Peroxide provides Clues to Immunity, Wound Healing, Tumor Biology - Puroxi

A burst of hydrogen peroxide causes neutrophils, the immune system’s first responders, to rush to the wound to fight microorganisms, remove damaged tissue and then start the inflammation process. University of Wisconsin-Madison researchers now have discovered the molecular sensor that detects wound-induced hydrogen peroxide and orchestrates the marshalling of neutrophils ...

ByPuroxi Pure Water Global Inc.


DermBiont Announces Positive Results in Phase 2a Clinical Trial in Atopic Dermatitis with a Topical Live Biotherapeutic

DermBiont Announces Positive Results in Phase 2a Clinical Trial in Atopic Dermatitis with a Topical Live Biotherapeutic

Patients are characterized by a genetic defect in epidermal barrier function, deficient antibacterial defenses, chronic inflammation, and a dysbiosis characterized by a marked decrease in microbial diversity and an increase in S. aureus. ...

ByDermBiont, Inc.


SetPoint Medical Receives FDA Breakthrough Device Designation for its Novel Bioelectronic Platform

SetPoint Medical Receives FDA Breakthrough Device Designation for its Novel Bioelectronic Platform

The Company is developing its platform for the treatment of chronic, inflammation-mediated autoimmune diseases, and is initially focused on the treatment of RA as a potentially efficacious, yet less immunosuppressive option. ...

BySetpoint Medical Corporation


Nuritas announce peer reviewed publication of world’s first AI discovered anti-inflammatory

Nuritas announce peer reviewed publication of world’s first AI discovered anti-inflammatory

The paper outlines the discovery of natural rice-based peptides clinically proven to impact inflammation and improve physical test results in an elderly population. ...

ByNuritas Ltd.


Alkahest Initiates a Phase 2 Clinical Trial of AKST4290 in Parkinson’s Disease with Funding from The Michael J. Fox Foundation

Alkahest Initiates a Phase 2 Clinical Trial of AKST4290 in Parkinson’s Disease with Funding from The Michael J. Fox Foundation

“AKST4290 suppresses immune-mediated pathways and chronic inflammation and, if effective, could represent an important step forward in the treatment of Parkinson’s disease. ...

ByAlkahest, Inc.


SFA Therapeutics, Inc. Receives an FDA Orphan Drug Designation (ODD) for SFA001 in the Treatment of Hepatocellular Carcinoma (HCC)

SFA Therapeutics, Inc. Receives an FDA Orphan Drug Designation (ODD) for SFA001 in the Treatment of Hepatocellular Carcinoma (HCC)

About SFA Therapeutics SFA Therapeutics, Inc. is a bio-pharmaceutical company focused on new human-microbiome-based advancements in the treatment of inflammatory diseases, targeting NF-kB. Chronic inflammation has been implicated in a wide range of diseases, including HCC, Psoriatic Arthritis, Rheumatoid Arthritis, Lupus (SLE), Inflammatory Bowel Disease (IBD), ...

BySFA Therapeutics, Inc.


Ivantis Completes Enrollment of International SPECTRUM Registry for Hydrus Microstent

Ivantis Completes Enrollment of International SPECTRUM Registry for Hydrus Microstent

The safety and effectiveness of the Hydrus® Microstent has not been established as an alternative to the primary treatment of glaucoma with medications, in patients 21 years or younger, eyes with significant prior trauma, eyes with abnormal anterior segment, eyes with chronic inflammation, eyes with glaucoma associated with vascular disorders, eyes with ...

ByIvantis, Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About

Channels

Solutions

  • Industry Products
  • Industry Software
  • Industry Training
  • Industry Services
  • Industry Applications

Latest

  • Industry News
  • Industry Events

Publications

  • Industry Articles
  • Industry Books
  • Industry Magazines
  • Industry Downloads
  • Industry Videos

Companies

  • Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
Medical XPRT
XPRT